Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy.

Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Original Publication: [Lausanne : Frontiers Media]

Breast cancer (BC) is one of the most prevalent types of cancer worldwide with high morbidity and mortality rates. Treatment modalities include systemic therapy, in which chemotherapy is a major component in many cases. Several chemotherapeutic agents are used in combinations or as single agents with many adverse events occurring in variable frequencies. These events can be a significant barrier in completing the treatment regimens. Germline genomic variants are thought of as potential determinants in chemotherapy response and the development of side effects. Some pharmacogenomic studies were designed to explore germline variants that can be used as biomarkers for predicting developing toxicity or adverse events during chemotherapy in BC. In this review, we reassess and summarize the major findings of pharmacogenomic studies of chemotherapy toxicity during BC management. In addition, deficiencies hampering utilizing these findings and the potential targets of future research are emphasized. Main insufficiencies in toxicity pharmacogenomics studies originate from study design, sample limitations, heterogeneity of selected genes, variants, and toxicity definitions. With the advent of high throughput genotyping techniques, researchers are expected to explore the identified as well as the potential genetic biomarkers of toxicity and efficacy to improve BC management. However, to achieve this, the limitations of previous work should be evaluated and avoided to reach more conclusive and translatable evidence for personalizing BC chemotherapy.
(Copyright © 2020 Al-Mahayri, Patrinos and Ali.)

Ann Oncol. 2019 Oct 1;30(10):1674. (PMID: 31236598)
Cancer Treat Rev. 2012 Aug;38(5):442-50. (PMID: 21917382)
Crit Rev Oncol Hematol. 2016 Apr;100:74-87. (PMID: 26857987)
Breast Cancer Res Treat. 2011 Dec;130(3):993-1002. (PMID: 21766209)
BMC Med. 2015 Aug 17;13:195. (PMID: 26278220)
Cell Rep. 2019 Aug 27;28(9):2345-2357.e5. (PMID: 31461651)
Pharmacogenomics. 2014;15(15):1845-58. (PMID: 25495407)
Eur J Cancer. 2017 Jan;71:15-24. (PMID: 27940354)
Nat Rev Clin Oncol. 2009 Nov;6(11):638-47. (PMID: 19786984)
Pharmacogenomics. 2016 Feb;17(3):231-40. (PMID: 26799497)
Ann Oncol. 2009 Feb;20(2):272-7. (PMID: 18836089)
Pharmacogenet Genomics. 2011 Mar;21(3):152-61. (PMID: 20216335)
PLoS One. 2016 Dec 30;11(12):e0168519. (PMID: 28036387)
N Engl J Med. 2019 May 16;380(20):1929-1940. (PMID: 31091374)
Ann Oncol. 2013 Jun;24(6):1472-8. (PMID: 23413280)
Clin Cancer Res. 2006 Sep 15;12(18):5496-502. (PMID: 17000685)
Pharmacogenomics. 2016 Oct;17(15):1607-1610. (PMID: 27676641)
Br J Clin Pharmacol. 2013 Jun;75(6):1497-505. (PMID: 23116553)
PLoS One. 2017 May 8;12(5):e0175998. (PMID: 28481884)
Clin Cancer Res. 2012 Sep 15;18(18):5099-109. (PMID: 22843789)
Clin Cancer Res. 2014 May 1;20(9):2466-75. (PMID: 24599932)
Eur J Hum Genet. 2020 Apr;28(4):508-517. (PMID: 31745289)
Breast Cancer Res Treat. 2015 Jul;152(1):67-76. (PMID: 26017071)
Breast Cancer Res Treat. 2018 Jan;167(1):249-256. (PMID: 28913729)
World J Surg Oncol. 2012 Jun 26;10:118. (PMID: 22734852)
Pharmacogenomics J. 2010 Feb;10(1):62-9. (PMID: 19752884)
Lancet. 2012 Feb 4;379(9814):432-44. (PMID: 22152853)
J Clin Diagn Res. 2015 Dec;9(12):FC01-6. (PMID: 26870703)
Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536. (PMID: 31008668)
Biol Sex Differ. 2018 Aug 29;9(1):38. (PMID: 30157941)
Eur J Cancer. 2012 Jan;48(1):1-11. (PMID: 21741830)
Cancers (Basel). 2018 Dec 12;10(12):. (PMID: 30545124)
Clin Breast Cancer. 2016 Oct;16(5):379-388. (PMID: 27212474)
Yonsei Med J. 2019 Jan;60(1):30-37. (PMID: 30554488)
Pharmacogenomics. 2009 Dec;10(12):1897-903. (PMID: 19958089)
Hum Pathol. 2017 Jul;65:31-40. (PMID: 28188752)
J Adv Pract Oncol. 2012 Jul;3(4):209-24. (PMID: 25031949)
Clin Cancer Res. 2017 Jan 1;23(1):43-51. (PMID: 27993963)
Pharmacol Res. 2018 Nov;137:104-113. (PMID: 30278221)
J Hum Genet. 2009 Oct;54(10):564-71. (PMID: 19696793)
Cancer Commun (Lond). 2018 Dec 4;38(1):71. (PMID: 30514381)
Pharmacogenet Genomics. 2008 Jul;18(7):621-31. (PMID: 18551042)
Cancer Treat Rev. 2015 Dec;41(10):935-50. (PMID: 26585358)
BMJ. 2005 Jan 29;330(7485):217. (PMID: 15649903)
Br J Cancer. 2010 Mar 16;102(6):1003-9. (PMID: 20179710)
Pharmacogenomics. 2016 Mar;17(4):435-51. (PMID: 26894782)
Support Care Cancer. 2016 May;24(5):2173-2180. (PMID: 26563179)
Pharmacogenomics. 2012 Jan;13(2):171-8. (PMID: 22188361)
Br J Cancer. 2016 Nov 22;115(11):1335-1342. (PMID: 27736846)
Onco Targets Ther. 2016 Aug 12;9:5073-80. (PMID: 27574448)
Clin Chim Acta. 2009 Jun 27;404(2):160-5. (PMID: 19332043)
Biochem Genet. 2015 Aug;53(7-8):211-22. (PMID: 26014925)
Ann Oncol. 2011 Sep;22(9):1939-1947. (PMID: 21289366)
Cancer Biol Ther. 2012 Mar;13(5):264-71. (PMID: 22310978)
Cancer Epidemiol. 2010 Oct;34(5):634-8. (PMID: 20638924)
Cancer Chemother Pharmacol. 2012 May;69(5):1221-7. (PMID: 22271208)
Breast Cancer Res Treat. 2010 Nov;124(2):433-9. (PMID: 20309628)
Acta Oncol. 2015 Apr;54(4):530-7. (PMID: 25383449)
EPMA J. 2015 Jul 22;6(1):15. (PMID: 26203310)
Breast Cancer Res Treat. 2015 Sep;153(2):383-9. (PMID: 26318989)
Oncotarget. 2017 Dec 19;9(6):7148-7161. (PMID: 29467957)
Front Pharmacol. 2018 Mar 13;9:158. (PMID: 29593529)
N Engl J Med. 2019 Feb 14;380(7):617-628. (PMID: 30516102)
Anticancer Res. 2017 May;37(5):2633-2639. (PMID: 28476838)
J Cancer Res Clin Oncol. 2013 Mar;139(3):419-27. (PMID: 23143606)
J Pathol. 2011 Jan;223(1):15-27. (PMID: 20818641)
JAMA Oncol. 2017 Nov 1;3(11):1538-1545. (PMID: 28715540)
Front Pharmacol. 2018 Mar 22;9:245. (PMID: 29623040)
Contemp Oncol (Pozn). 2013;17(1):78-82. (PMID: 23788967)
Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1201-10. (PMID: 21919804)
Sci Rep. 2017 Dec;7(1):39. (PMID: 28232737)
Breast Cancer Res Treat. 2010 Nov;124(2):593-8. (PMID: 20632082)
Recent Pat DNA Gene Seq. 2012 Apr;6(1):33-46. (PMID: 22239682)
Ther Adv Med Oncol. 2019 Feb 25;11:1758835919827714. (PMID: 30833989)
Cancer Treat Rev. 2015 Feb;41(2):197-215. (PMID: 25579752)
Pharmacogenomics J. 2014 Jun;14(3):241-7. (PMID: 23999597)
Cancer Chemother Pharmacol. 2015 Jan;75(1):207-14. (PMID: 25428516)
Mol Diagn Ther. 2013 Dec;17(6):371-9. (PMID: 23812950)
Pharmacogenomics. 2012 Apr;13(6):677-90. (PMID: 22515610)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Pharmacogenomics. 2011 Oct;12(10):1417-27. (PMID: 21902499)
Clin Pharmacol Ther. 2008 Jan;83(1):160-6. (PMID: 17882159)
Theor Biol Med Model. 2016 Feb 29;13:7. (PMID: 26925829)
Cancer Epidemiol. 2013 Oct;37(5):754-61. (PMID: 23707158)
Cancer. 2017 Jun 1;123(11):1925-1934. (PMID: 28117882)
Nat Rev Cancer. 2004 Apr;4(4):253-65. (PMID: 15057285)
Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186. (PMID: 28447211)
Drugs. 2019 Jul;79(11):1217-1230. (PMID: 31254268)
JAMA Oncol. 2015 Dec;1(9):1311-8. (PMID: 26402167)
Breast Cancer Res Treat. 2014 May;145(1):245-54. (PMID: 24706167)

Keywords: breast cancer; chemotherapy; pharmacogenomics; side effects; toxicity

Date Created: 20200501 Latest Revision: 20210110

20240513

PMC7174767

10.3389/fphar.2020.00445

32351390